Evidence map›Paper›PMID 40843597›Full record

GuidelineActa dermato-venereologica2025

European S2k Guideline on Chronic Pruritus

Elke Weisshaar, Simon Müller, Jacek C Szepietowski, Florence Dalgard, Simone Garcovich, Jörg Kupfer, Ana Gimenez-Arnau, Julien Lambert, Thomas Mettang, Laurent Misery and 4 more

Abstract readPractice Guideline
In one paragraph

Guideline in Acta dermato-venereologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Modern wITCHcraft: Conjuring pruritus-associated gene signatures through microarray profiling.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026
    Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Elke WeisshaarSection of Occupational Dermatology, Department of Dermatology, Ruprecht-Karls-University Heidelberg, Germany. elke.weisshaar@med.uni-heidelberg.de.
Simon MüllerDepartment of Dermatology, Universitätsspital Basel, Switzerland.
Jacek C SzepietowskiDepartment of Dermato-Venereology, Faculty of Medicine, 4th Military Hospital, Wroclaw University of Science and Technology, Wroclaw, Poland, and Wroclaw Medical University, Poland.
Florence DalgardDepartment of Psychiatry, Vestfold Hospital Trust, Tønsberg, Norway and Department of Dermatology and Venerology, Skane University Hospital, Lund University, Malmö, Sweden.
Simone GarcovichInstitute of Dermatology, F. Policlinico Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.
Jörg KupferInstitute of Medical Psychology, Justus-Liebig University of Giessen, Germany.
Ana Gimenez-ArnauDepartment of Dermatology, Hospital del Mar-Institut Mar d'Investigacions Mèdiques (IMIM), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
Julien LambertDepartment of Dermatology, University Hospital of Antwerp, University of Antwerp, Belgium.
Thomas MettangDepartment of Nephrology, DKD Helios Wiesbaden, Germany.
Laurent MiseryDepartment of Dermatology, University Hospital Brest, France.
Ekin SavkDepartment of Dermatology, Aydin Adnan Menderes University, Aydin, Turkey.
Erwin TschachlerDepartment of Dermatology and Venereology, Lund University, Lund, Sweden.
Joanna WallengrenDepartment of Dermatology and Venereology, Lund University, Lund, Sweden.
Sonja StänderSection for Pruritus Medicine, Department of Dermatology and Center for Chronic Pruritus, University Hospital Muenster, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pruritus is a frequent symptom in medicine. Population-based studies show that one in five persons in the general population has suffered from chronic pruritus (CP) at least once in their lifetime, with a 12-month incidence of 7%. CP, which can affect all age groups, is associated with numerous, often interdisciplinary medical conditions. It needs a precise diagnostic work-up to identify causes and relevant comorbidities. Management of CP comprises treatment of the underlying disease as well as topical and systemic therapies. Treating CP needs to be targeted, multimodal and performed in a step-wise procedure requiring an interdisciplinary approach. In recent years, novel on-label therapies have been approved for CP, including therapies for chronic prurigo and cholestatic pruritus. We present the updated European guideline on chronic pruritus by a team of European pruritus experts from different disciplines.

Indexed as

AntipruriticsDermatologyPruritusChronic DiseaseConsensusEuropeHumansTreatment OutcomeAntipruritics

Identifiers

PMID40843597
PMCPMC12529596

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.